As for risk gene SLC2A3, the expression had a positive correlation with drug sensitivity of cancer cells to Trametinib, but showed a negative correlation with drug sensitivity of cancer cells to Palbociclib and Carfilzomib (Figures 11M–O). Here, SLC2A3 is linked to cancer.